Background/Objectives: Ovarian cancer (OC) remains one of the most lethal gynecologic malignancies, largely due to the challenges of early detection. While next-generation sequencing (NGS) has been explored for screening, its high cost limits large-scale implementation. To develop a more accessible diagnostic solution, we designed a qPCR-based algorithm optimized for early OC detection, with a focus on high-grade serous ovarian cancer (HGSOC), the most aggressive subtype. Methods: Peripheral blood samples from 19 ovarian cancer patients, 37 benign tumor patients, and 34 asymptomatic controls were analyzed using RNA sequencing to identify splice junction-based biomarkers with minimal expression in benign samples but elevated in OC. Results: A final panel of 10 markers was validated via qPCR, demonstrating strong agreement with sequencing data (R2 = 0.44–0.98). The classification algorithm achieved 94.1% sensitivity and 94.4% specificity (AUC = 0.933). Conclusions: By leveraging platelet RNA profiling, this approach offers high specificity, accessibility, and potential for early OC detection. Future studies will focus on expanding histologic diversity and refining biomarker panels to further enhance diagnostic performance.
Tumor-educated platelets (TEPs) are emerging as powerful minimally invasive liquid bi-opsy modalities for cancer diagnosis and prognosis. Through crosstalk with tumor cells, platelets sequester tumor-derived molecules and exhibit altered RNA splicing, protein content, and activation status, all of which reflect tumor biology. Numerous studies have reported that TEP-based assays can distinguish cancer patients from controls, with sensi-tivities and specificities often exceeding 80%. Furthermore, platelet RNA signatures can identify cancer types and stages, and elevated platelet counts (thrombocytosis) and spe-cific platelet RNA/protein biomarkers are correlated with adverse prognoses in multiple malignancies, including ovarian and lung cancers. Recent large-scale investigations have validated these findings, reinforcing that TEPs are promising diagnostic and prognostic indicators. Despite this potential, some challenges remain. Ensuring sufficient platelet purity, standardizing sample processing, and accounting for non-cancerous conditions that influence platelet profiles remain critical hurdles. Moreover, tumor heterogeneity and dynamic platelet “education” can complicate assay interpretation. Ongoing efforts are focused on refining biomarker panels, improving computational models for classification, and integrating TEP data with other liquid biopsy analytes (e.g., circulating tumor DNA) for enhanced accuracy. Overall, TEP-based liquid biopsy could transform clinical deci-sion-making by enabling the earlier detection of malignancies and more precise prognos-tic assessments. With further validation in large prospective trials, TEP assays may soon provide a routine and cost-effective approach for guiding individualized cancer care.
Background: Ovarian cancer is the most lethal gynecologic malignancy, and CA-125 has limited early-stage sensitivity. We developed and evaluated Foretell Ovary, an ensemble machine-learning classifier that integrates tumor-educated-platelet RNA markers and routine hematologic parameters for non-invasive ovarian cancer detection, and compared it head-to-head with CA-125. Methods: A multi-site prospective cohort study enrolled 460 South Korean participants (67 ovarian cancer, 15 borderline ovarian tumors, 197 benign gynecological conditions, and 181 asymptomatic controls) at six clinical sites between September 2024 and March 2026. The cohort was split into training (n = 279) and independent test (n = 181) sets under a pre-specified ACTB cycle threshold ≤ 28 per-protocol rule (test n = 169). The classifier blended a random forest and two calibrated logistic-regression sub-models built on eight platelet RNA markers, 24 complete blood count parameters, and 30 marker-by-hematology combination features. Performance was assessed at a pre-frozen cutoff of 0.44 and compared against CA-125 (35 U/mL cutoff) in a matched subset (n = 100). Results: Foretell Ovary achieved an area under the receiver operating characteristic curve (AUC) of 0.923, sensitivity of 87.5% (100.0% for Stage II–IV), specificity of 89.0%, and negative predictive value of 97.7% in the test set. In the matched subset, Foretell Ovary outperformed CA-125 on every metric (AUC 0.839 vs. 0.723; sensitivity 85.0% vs. 65.0%), with the largest gap in pre-menopausal participants (+25 percentage points in sensitivity). A three-tier risk-grading scheme retained no ovarian cancer in the low-risk grade. Conclusions: Foretell Ovary offers more accurate non-invasive detection of ovarian cancer than CA-125, particularly in pre-menopausal women, offering the flexibility to be used alone or combined with CA-125. Prospective validation studies are warranted.